Review on Targeting the DNA Damaging Pathway: PARPi and Beyond
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors—proceedings from breast cancer expert group meeting
Shaheenah Dawood, Maria Konstantinova, Florencia Perazzo, Sung-Bae Kim, Cynthia Villarreal-Garza, Sandra Ximena Franco, Sergio D. Simon, Tamer El-Nahas
